BPC-157: What the Preclinical Record Actually Shows
BPC-157 is the most requested research peptide in the US market and one of the most poorly described. Vendor copy and forum summaries have converged on a set of claims that the underlying literature only partly supports, and the gap between the two is wide enough that any laboratory designing work around this compound should read the primary record rather than the secondary one.
This review covers what has been published in animal models and cell culture, which mechanisms have direct experimental support, and — the part usually omitted — where the evidence base is structurally weak. Material discussed here is supplied for research use only and is not for human use.
Origin and structure
BPC-157 is a synthetic pentadecapeptide: fifteen amino acids, sequence GEPPPGKPADDAGLV, molecular weight approximately 1419 Da. It was derived from a partial sequence of Body Protection Compound, a protein fraction identified in gastric juice by Sikirić and colleagues at the University of Zagreb, whose group has produced the majority of the in vivo literature on the molecule over roughly three decades.
Two structural properties shape how it is studied. First, it carries no cysteine residues and forms no disulfide bridges, which removes the oxidation and scrambling pathways that complicate work with many other peptides. Second, the Zagreb group has reported that the peptide remains stable in gastric juice for extended periods — an unusual property for a peptide of this length, and the basis for the oral and intragastric routes used in a large fraction of the rodent studies.
Tendon, ligament and bone models
The musculoskeletal literature is the most developed part of the record and the most methodologically varied, because it includes work from groups outside Zagreb.
Chang and colleagues (J Appl Physiol, 2011) examined rat Achilles tendon explants and cultured tendon fibroblasts, reporting increased tendon fibroblast outgrowth, survival and migration in the presence of BPC-157, with the effect associated with activation of the FAK–paxillin pathway. The same group later reported upregulated growth hormone receptor expression in tendon fibroblasts exposed to the peptide (Molecules, 2014), proposing a mechanism by which local sensitivity to circulating growth hormone might be modulated at the tissue level rather than systemically. These are in vitro and ex vivo findings with an identified signaling pathway, which makes them among the more mechanistically substantive results in the field.
Krivic and colleagues (J Orthop Res, 2006) used a rat Achilles tendon-to-bone detachment model and reported accelerated functional recovery relative to control, and — notably — an opposing effect against corticosteroid-induced aggravation in the same model. Cerovecki and colleagues (J Orthop Res, 2010) reported comparable findings in a rat medial collateral ligament transection model.
The bone work predates most of the soft tissue literature. Sebecić and colleagues (Bone, 1999) reported improved healing of a segmental bone defect in rabbits, one of the few studies in the corpus using a non-rodent species.
Gwyer, Wragg and Wilson (Cell Tissue Res, 2019) reviewed this cluster and reached a measured conclusion worth quoting in spirit: the musculoskeletal findings are consistent across models, but the corpus is dominated by a small number of laboratories and would benefit substantially from independent replication at scale.
Angiogenesis and the VEGFR2 axis
The vascular work is where BPC-157 has its clearest proposed mechanism.
Hsieh and colleagues (J Mol Med, 2017) reported that BPC-157 promotes angiogenesis through activation and upregulation of VEGFR2, using human umbilical vein endothelial cells in vitro alongside an in vivo model, with downstream signaling through the VEGFR2–Akt–eNOS pathway. The endpoint measures — endothelial cell proliferation, tube formation, migration — are standard for the field, and the receptor-level identification distinguishes this work from studies reporting only that vascularization improved.
Huang and colleagues (Drug Des Devel Ther, 2015) reported accelerated closure in a rat alkali-burn model together with in vitro proliferation, migration and angiogenesis effects, converging with Hsieh’s result from a different starting point.
Earlier, Tkalcević and colleagues (Eur J Pharmacol, 2007) examined PL 14736 — the pharmaceutical designation for the same pentadecapeptide during Pliva’s development program — in rat wound models, reporting enhanced granulation tissue formation and improved collagen organization, with early growth response protein 1 (EGR-1) proposed as a transcriptional mediator. EGR-1 sits upstream of a range of cytokine and growth factor responses, which makes it a plausible integration point for the diverse effects reported across tissue types.
Seiwerth and colleagues (Curr Pharm Des, 2018) synthesized the angiogenic literature and argued that BPC-157’s profile differs from that of standard angiogenic growth factors in that the reported vascular responses appear self-limiting rather than escalating. That distinction is interesting and under-tested.
The nitric oxide system
A recurring finding across the Zagreb corpus is that BPC-157’s effects in rat models interact with nitric oxide signaling. The characteristic experimental design co-administers L-NAME, a nitric oxide synthase inhibitor, or L-arginine, a substrate, and observes whether the peptide’s effect is attenuated or potentiated. Across multiple rat models the reported pattern is that BPC-157 counteracts L-NAME-induced effects and modulates the L-arginine response, which the authors interpret as evidence that the peptide acts on the NO system rather than through a single dedicated receptor.
This is a mechanistically important claim and also the least resolved one in the literature. No specific high-affinity BPC-157 receptor has been identified and characterized. The absence of an identified binding target is the central open question for the compound, and any laboratory reading the mechanism sections of this literature should hold that in view: pathway-level association is not the same thing as receptor-level identification.
Related vascular work from the same group — including Vukojević and colleagues’ rat inferior caval vein ligature studies — has proposed that the peptide influences the recruitment of collateral vascular pathways, extending the angiogenesis findings into a whole-organism context.
Where the evidence base is thin
An honest review has to state the limitations plainly, because vendor summaries almost never do.
Concentration of authorship. A large majority of the in vivo literature originates from a single research group. That group’s work is extensive and internally consistent, but concentration of authorship is a recognized source of systematic bias in any evidence base, and independent replication of the core in vivo findings remains limited relative to the volume of published claims.
Species and model range. The corpus is overwhelmingly rat, with a small number of rabbit and mouse studies. Peptide pharmacokinetics differ substantially across species, and rodent findings do not transfer automatically.
Pharmacokinetics. Published absorption, distribution, metabolism and excretion data for BPC-157 are sparse. For a molecule reported to be active by intragastric administration, the absence of well-characterized bioavailability and plasma half-life data in the open literature is a real gap.
Clinical record. PL 14736 entered Phase II evaluation for inflammatory bowel indications under Pliva. That program did not proceed to registration, and there is no approved product. In October 2023 the US Food and Drug Administration placed BPC-157 in Category 2 of its bulk drug substances review for 503A compounding — the category indicating significant safety risks — which means that in the United States this compound’s regulatory position is explicitly that of an unapproved substance. That designation is the reason material of this kind is supplied to laboratories on research-use terms and no other.
Handling considerations for laboratory work
BPC-157 is supplied lyophilized. The absence of cysteine removes disulfide scrambling from the degradation picture, but the standard peptide pathways still apply: hydrolysis and deamidation in solution, aggregation under unfavorable pH or ionic conditions, and adsorptive loss to labware surfaces at low concentrations. Lyophilized vials stored cold, dark and dry are stable over practical timescales; reconstituted material is not, and repeated freeze-thaw cycling is the most common avoidable source of variability in peptide bench work.
Because BPC-157 sequences are short and synthesis is well established, purity differences between suppliers tend to show up not as gross impurities but as counterion content, residual solvent and net peptide content discrepancies — which is why the certificate of analysis matters more than the headline purity percentage. A 99% HPLC purity figure says nothing about how much of the vial’s mass is actually peptide rather than trifluoroacetate and water.
Summary
BPC-157 has a genuine preclinical literature with identified signaling pathways — FAK–paxillin in tendon fibroblasts, VEGFR2–Akt–eNOS in endothelium, EGR-1 in granulation tissue — and consistent findings across rat musculoskeletal and wound models. It also has no identified receptor, sparse pharmacokinetic characterization, heavy authorship concentration, and no approved clinical product. Both halves of that description are true, and a laboratory designing work with this compound is better served by holding them together than by reading either one alone.
Maple Research Labs supplies BPC-157 10mg with batch certificate of analysis, shipped domestically from Santa Barbara with the certificate published against the lot in the box.
All compounds supplied by Maple Research Labs are provided strictly for research use only in controlled laboratory settings. They are not for human use, not intended for human or veterinary application, and not intended to diagnose, treat, cure or prevent any condition. Purchasers are responsible for compliance with all applicable institutional and regulatory requirements.